Find information on thousands of medical conditions and prescription drugs.

Pheochromocytoma

A pheochromocytoma (also phaeochromocytoma, English spelling) is a tumor of the medulla of the adrenal glands originating in the chromaffin cells, which secretes excessive amounts of catecholamines, usually epinephrine and norepinephrine. Extra-adrenal paragangliomas (often described as extra-adrenal pheochromocytomas) are closely related, though less common, tumors that originate in the ganglia of the sympathetic nervous system and are named based upon the primary anatomic site of origin. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Arthritis
Arthritis
Bubonic plague
Hypokalemia
Pachydermoperiostosis
Pachygyria
Pacman syndrome
Paget's disease of bone
Paget's disease of the...
Palmoplantar Keratoderma
Pancreas divisum
Pancreatic cancer
Panhypopituitarism
Panic disorder
Panniculitis
Panophobia
Panthophobia
Papilledema
Paraganglioma
Paramyotonia congenita
Paraphilia
Paraplegia
Parapsoriasis
Parasitophobia
Parkinson's disease
Parkinson's disease
Parkinsonism
Paroxysmal nocturnal...
Patau syndrome
Patent ductus arteriosus
Pathophobia
Patterson...
Pediculosis
Pelizaeus-Merzbacher disease
Pelvic inflammatory disease
Pelvic lipomatosis
Pemphigus
Pemphigus
Pemphigus
Pendred syndrome
Periarteritis nodosa
Perinatal infections
Periodontal disease
Peripartum cardiomyopathy
Peripheral neuropathy
Peritonitis
Periventricular leukomalacia
Pernicious anemia
Perniosis
Persistent sexual arousal...
Pertussis
Pes planus
Peutz-Jeghers syndrome
Peyronie disease
Pfeiffer syndrome
Pharmacophobia
Phenylketonuria
Pheochromocytoma
Photosensitive epilepsy
Pica (disorder)
Pickardt syndrome
Pili multigemini
Pilonidal cyst
Pinta
PIRA
Pityriasis lichenoides...
Pityriasis lichenoides et...
Pityriasis rubra pilaris
Placental abruption
Pleural effusion
Pleurisy
Pleuritis
Plummer-Vinson syndrome
Pneumoconiosis
Pneumocystis jiroveci...
Pneumocystosis
Pneumonia, eosinophilic
Pneumothorax
POEMS syndrome
Poland syndrome
Poliomyelitis
Polyarteritis nodosa
Polyarthritis
Polychondritis
Polycystic kidney disease
Polycystic ovarian syndrome
Polycythemia vera
Polydactyly
Polymyalgia rheumatica
Polymyositis
Polyostotic fibrous...
Pompe's disease
Popliteal pterygium syndrome
Porencephaly
Porphyria
Porphyria cutanea tarda
Portal hypertension
Portal vein thrombosis
Post Polio syndrome
Post-traumatic stress...
Postural hypotension
Potophobia
Poxviridae disease
Prader-Willi syndrome
Precocious puberty
Preeclampsia
Premature aging
Premenstrual dysphoric...
Presbycusis
Primary biliary cirrhosis
Primary ciliary dyskinesia
Primary hyperparathyroidism
Primary lateral sclerosis
Primary progressive aphasia
Primary pulmonary...
Primary sclerosing...
Prinzmetal's variant angina
Proconvertin deficiency,...
Proctitis
Progeria
Progressive external...
Progressive multifocal...
Progressive supranuclear...
Prostatitis
Protein S deficiency
Protein-energy malnutrition
Proteus syndrome
Prune belly syndrome
Pseudocholinesterase...
Pseudogout
Pseudohermaphroditism
Pseudohypoparathyroidism
Pseudomyxoma peritonei
Pseudotumor cerebri
Pseudovaginal...
Pseudoxanthoma elasticum
Psittacosis
Psoriasis
Psychogenic polydipsia
Psychophysiologic Disorders
Pterygium
Ptosis
Pubic lice
Puerperal fever
Pulmonary alveolar...
Pulmonary hypertension
Pulmonary sequestration
Pulmonary valve stenosis
Pulmonic stenosis
Pure red cell aplasia
Purpura
Purpura, Schoenlein-Henoch
Purpura, thrombotic...
Pyelonephritis
Pyoderma gangrenosum
Pyomyositis
Pyrexiophobia
Pyrophobia
Pyropoikilocytosis
Pyrosis
Pyruvate kinase deficiency
Uveitis
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Inheritance

Up to 25% of pheochromocytomas may be familial. Mutations of the genes VHL, RET, NF1, SDHB and SDHD are all known to cause familial pheochromocytoma/extra-adrenal paraganglioma.

Features

The signs and symptoms of a pheochromocytoma are those of sympathetic nervous system hyperactivity:

  • elevated heart rate
  • elevated blood pressure
  • palpitations
  • anxiety often resembling that of a panic attack
  • diaphoresis
  • headaches

A pheochromocytoma can also cause resistant arterial hypertension. A pheochromocytoma can be fatal if it causes malignant hypertension, or severely high blood pressure.

Diagnosis

The diagnosis can be established by measuring catecholamine and metanefrine in plasma or urine. One diagnostic test used in the past for a pheochromocytoma is to administer clonidine (Catapres®), a centrally-acting alpha-2 agonist used to treat high blood pressure. Clonidine mimics catecholamines in the brain, causing it to reduce the activity of the sympathetic nerves controlling the adrenal medulla. A healthy adrenal medulla will respond to clonidine by reducing catecholamine production; the lack of a response is evidence of pheochromocytoma. Another test is for the clinician to press gently on the adrenal gland. A pheochromocytoma will often release a burst of catecholamines, with the associated signs and symptoms quickly following.

Pheochromocytomae occur most often during young-adult to mid-adult life. Less than 10% of pheochromocytomas are malignant (cancerous).

These tumors can form a pattern with other endocrine gland cancers which is labelled multiple endocrine neoplasia (MEN). Pheochromocytoma may occur in patients with MEN 2a and MEN 2b.

Differential diagnosis

The differential diagnosis of pheochromocytoma includes:

  • Anxiety disorders
  • Carcinoid tumor
  • Essential hypertension
  • Hyperthyroidism
  • Insulinoma
  • Paroxysmal supraventricular tachycardia
  • Renovascular hypertension

Treatment

Surgical resection of the tumor is the treatment of first choice.

Read more at Wikipedia.org


[List your site here Free!]


Maxillary giant cell granuloma, pheochromocytoma, and hyperparathyroidism without medullary thyroid carcinoma
From Ear, Nose & Throat Journal, 8/1/00 by Ruth McManus

Abstract

We examined a young man who had a benign giant cell granuloma of the maxilla, which we subsequently diagnosed as a brown tumor associated with hyperparathyroidism. During surgery for the granuloma, the patient developed severe hypertension and was discovered to have an extra-adrenal pheochromocytoma. Oncogene and calcitonin testing for medullary carcinoma of the thyroid was negative. Therefore, despite the presence of both pheochromocytoma and hyperparathyroidism, we concluded that this patient did not have multiple endocrine neoplasia type 2a.

Introduction

We report an unusual case of a patient who had a maxillary brown tumor associated with hyperparathyroidism and an extra-adrenal pheochromocytoma. The fact that there was no medullary thyroid cancer provided evidence that the man did not have multiple endocrine neoplasia (MEN) type 2a.

Case report

A 23-year-old man reported a painful swelling in the right maxilla of 5 months' duration. The patient denied any symptoms of episodic headache, sweating, or palpitations. He had no history of hypertension, thirst, polyuria, or fatigue. He was taking no medication and did not use recreational drugs. His family history was negative for any known abnormalities. The physical examination, including an evaluation of the skin and the thyroid gland, was unremarkable. In particular, he had no manifestation of neurofibromatosis or von Hippel-Lindau disease.

Computed tomography (CT) of the right maxilla suggested the presence of a tumor and showed associated bony destruction and displacement of the dentition (figure 1). The patient underwent an uneventful partial right maxillectomy under general anesthesia, and a 5.2 X 2.4 x 3.5-cm mass was removed. The tumor's pathology was consistent with that of a benign central giant cell tumor (figure 2).

Following surgery, the patient continued to experience progressively worsening facial discomfort. Followup maxillary CT at 6 months detected no decrease in the size of the original tumor area, and he was readmitted for further surgical treatment. Upon the introduction of general anesthesia, the patient experienced an immediate rise in blood pressure--from 120/80 to 200/140mm Hg--and a regular tachycardia of 150 beats per minute. General anesthesia was promptly halted, and further investigations were undertaken.

Laboratory tests. The patient's serum calcium level was 14.0 mg/dl (normal: 8.5-10.5), his phosphate level was 2.38 mg/dl (normal: 2.48-4.49), and his albumin was normal. His intact parathyroid hormone level was 1,116 pg/ml (normal: 10-60). Serum catecholamines drawn at rest through an indwelling line showed norepinephrine at 3,158 pg/ml (normal: [less than]473), epinephrine at 48.3 pg/ml (normal: [less than]59), and dopamine at 35.2 pg/ml (normal: [less than]32). Twenty-four-hour urine collection showed metanephrine at 128 [micro]g/mg Cr (normal: [less than] 216), normetanephrine at 2,899 [micro]g/mg Cr (normal: [less than]477), and vanillylmandelic acid at 13.2 mg/day (normal: [less than]6.7). His basal calcitonin concentration was 28.7 pg/ml (normal: [less than]100) and did not rise on pentagastrin stimulation. RET oncogene testing showed only normal sequences in exons 10, 11, and 13. A mutation (MET 918Thy) in RET exon 16 was ruled out by restriction enzyme analysis.

Imaging. Ultrasound of the abdomen suggested the presence of a vascular mass anterior and superior to the urinary bladder, and magnetic resonance imaging detected a 5.0 x 3.0 x 3.5-cm growth there (figure 3). Ultrasound of the neck also suggested the presence of a mass in the left thyroid. Meta-iodobenzyl guanidine [123]I and somatostatin scans were both negative. No adrenal gland abnormality was seen.

We concluded that the patient had both pheochromocytoma and hyperparathyroidism, and that removal of the pheochromocytoma would take precedence. After 3 weeks of phenoxybenzamine preparation, the patient was admitted to the hospital for 12 hours of intravenous fluid repletion. Surgical exploration detected a mass on the anterior wall of the urinary bladder. Upon manipulation of the mass, the patient's blood pressure rose to 180/110mm Hg; it immediately returned to normal when the blood supply to the tumor was clamped. The postoperative course was uneventful. Pathology of the tumor was consistent with that of an extra-adrenal pheochromocytoma. Followup urine collections for catecholamine products were negative.

Two months later, the patient was readmitted for exploration of the thyroid gland. A 3.0 x 1.0 x 1.5-cm mass was removed from the left inferior lobe. Other parathyroid glands were biopsied, and pathology indicated the presence of a single parathyroid adenoma without parathyroid hyperplasia in the other glands. Other than transient postoperative hypocalcemia, the patient has remained well and has maintained normal calcium levels without the need for supplements.

Discussion

This patient with a giant cell granuloma of the maxilla went on to exhibit hyperparathyroidism and extra-adrenal pheochromocytoma. The unusual features of this case include the fact that the maxillary tumor was initially diagnosed as a benign central giant cell granuloma. This tumor is pathologically indistinguishable from a giant cell tumor of the bone or a brown tumor of hyperparathyroidism. Hyperparathyroidism has been previously noted to be a cause of these granulomas, [1] although more often they manifest in the distal femur or proximal tibia. Surgery was complicated in this case by the presence of an unexpected pheochromocytoma. There has been no previous report of a giant cell granuloma of hyperparathyroidism occurring in association with pheochromocytoma.

It was further expected that this patient would manifest the criteria for MEN type 2a, but there was significant evidence against this conclusion. The constant feature of MEN 2a is a medullary carcinoma of the thyroid, which was very unlikely in this case because of the normal pentagastrin stimulation test and, more important, the negative results on RET oncogene testing. The sensitivity of RET oncogene testing for MEN 2a has been reported to be as high as 97%, while pentagastrin stimulation of calcitonin might be only half as sensitive. [2,3] Moreover, although there have been some reports of solitary parathyroid adenomas in the setting of MEN 2a, it is more common for the associated abnormality to be a parathyroid hyperplasia. [4] Therefore, although this patient could possibly still develop a medullary carcinoma of the thyroid and hence fulfill the criteria for MEN 2a, this appears unlikely.

From the Division of Endocrinology and Metabolism, Department of Medicine, The University of Western Ontario, London, Canada.

References

(1.) Robinson PJ, Woodhead P. Primary hyperparathyroidism presenting with a maxillary tumour and hydrocephalus. J Laryngol Otol 1988;102:l164-7.

(2.) Barbot N, Calmettes C, Schuffenecker I, et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: Comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:114-20.

(3.) Heshmati HM, Gharib H, Khosla S, et al. Genetic testing in medullary thyroid carcinoma syndromes: Mutation types and clinical significance. Mayo Clinic Proc 1997;72:430-6.

(4.) Kraimps JL, Denizot A, Carnaille B, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: Retrospective French multicentric study. Groupe d'Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 1996;20:808-12.

COPYRIGHT 2000 Medquest Communications, Inc.
COPYRIGHT 2000 Gale Group

Return to Pheochromocytoma
Home Contact Resources Exchange Links ebay